Given The Success Of Virtual Investor Pitching, Do You Think Events Like JPM And BTS Will Remain Relevant?

Source: Life Science Leader
ATB_Martin Lehr_450x300.jpg

A | THE FIRST TIME I PITCHED VIRTUALLY I NOTICED DIFFERENCES. For example, in the virtual environment it is not possible to read the room like you can when pitching in person. So while COVID-19 has pushed us all into the world of pitching investors virtually, it is still uncertain how well small, private biotechs will fare in a virtual fundraising environment. Nevertheless, I believe virtual pitching to be a valuable tool. The connections made at in-person events seem difficult to replicate in a virtual setting, though. Thus, I imagine key industry in-person gatherings will remain relevant, assuming they can survive this current time period.

MARTIN LEHR is CEO and cofounder at Context Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing novel medicines for hormone receptor positive cancers.